Metabolic volume, lesion glycolysis in FDG-PET predict CRC survival

06/6/2013 |

Metabolic volume and lesion glycolysis as measured through 18F-FDG-PET performed better in predicting survival among radioembolization-treated patients with metastatic colorectal cancer than standardized guidelines for uptake, according to a study reported in The Journal of Nuclear Medicine. Patients who exhibited a change in metabolic volume had survival of 92 weeks, compared with 49 weeks, while for those with lesion glycolysis, survival was 91 weeks, compared with 48. Meanwhile, "changes in SUVpeak or SUVmax and RECIST 1.1 criteria did not predict survival," researchers wrote.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA